Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | ASCO 2024 highlights: the PSMAfore trial for patients with mCRPC

Wolfgang Fendler • 1 Jun 2024
ASCO 2024
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617
PSMAfore

Wolfgang Fendler, MD, University Hospital Essen, Essen, Germany, discusses the PSMAfore trial (NCT04689828), which enrolled patients with metastatic castration-resistant prostate cancer (mCRPC). This Phase III trial showed that 177Lu-PSMA-617, a prostate specific membrane antigen (PSMA) targeted radioligand therapy, is able to delay disease progression and increase the quality of life of patients with mCRPC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – Parexel
Consulting or Advisory Role – Calyx; Janssen
Speakers’ Bureau – ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding – SOFIE

More from Wolfgang Fendler

Assessing the role of PSMA-PET PROMISE nomograms in prostate cancer
1:11
Assessing the role of PSMA-PET PROMISE nomograms in prostate cancer
Wolfgang Fendler • 1 Jun 2024
Integration of PSMA-PET into routine clinical practice for patients with prostate cancer
0:41
Integration of PSMA-PET into routine clinical practice for patients with prostate cancer
Wolfgang Fendler • 1 Jun 2024

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals